Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis

Conclusion Prognosis may be significantly improved in cStage II/III ESCC patients who underwent DCF NAC than those with CF NAC. (Source: General Thoracic and Cardiovascular Surgery)

from squamous cell carcinoma via ok on Inoreader http://ift.tt/1PS8CU8
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1Qcs9KP
via IFTTT